Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2013-002023-41-NL
EUCTR2013-002023-41-NLActive, not recruitingPhase 1

Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer: IMPACT - CRC

VU University Medical Center0 sites151 target enrollmentStarted: August 30, 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
151
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Advanced colorectal adenocarcinoma
  • •Subjects must have been treated according to standard care with a fluoropyrimidine (e.g. fluorouracil or capecitabine), irinotecan, and oxaliplatin or had contra-indications to treatment with these drugs.
  • •Age = 18 years.
  • •Histological or cytological documentation of cancer is required.
  • •Tumor material must be tested wild type for the K-RAS and B-RAF gene.
  • •Tumor lesion:
  • •o Part I: Subjects have at least one measurable lesion = 2 cm outside the liver. Lesions must be evaluable by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
  • •o Part II: Subjects have at least one measurable tumor lesion = 1 cm, including liver tumor lesion. Lesions must be evaluable by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
  • •ECOG Performance Status of 0, 1 or 2
  • •Adequate liver and renal functions as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
  • •o Total bilirubin = 1.5 times the upper limit of normal
  • •o ALT and AST = 2.5 times upper limit of normal (= 5 times upper limit of normal for subjects with liver involvement of their cancer)
  • •o Serum creatinin = 1.5 times upper limit of normal or a calculated creatinin clearance = 50 ml/min
  • •Signed informed consent must be obtained prior to any study specific procedures.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 75
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 76

Exclusion Criteria

  • •Previous exposure to an anti-EGFR therapy
  • •Significant skin condition interfering with treatment
  • •Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must agree to use adequate barrier birth control measures (e.g., cervical cap, condom, and diaphragm) during the course of the trial. Oral birth control methods alone will not be considered adequate on this study, because of the potential pharmacokinetic interaction between study drug and oral contraceptives. Concomitant use of oral and barrier contraceptives is advised. Contraception is necessary for at least 6 months after receiving study drug.
  • •Concurrent anticancer chemotherapy, immunotherapy or investigational drug therapy during the study or within 4 weeks of the start of study drug.
  • •Radiotherapy to the target lesions during study or within 4 weeks of the start of study drug. Palliative radiotherapy will be allowed.
  • •Major surgery within 28 days of start of study drug.
  • •Substance abuse, medical, psychological or social conditions that may interfere with the subject’s participation in the study or evaluation of the study results.
  • •Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study.

Investigators

Sponsor
VU University Medical Center

Similar Trials

Completed
Phase 2
Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer: IMPACT - CRCmetastatic colorectal canceradvanced intestinal cancer10017991
NL-OMON50209Vrije Universiteit Medisch Centrum151
Recruiting
Not Applicable
Optimalisatie van de behandeling met cetuximab voor patienten met uitgezaaide dikkedarm kanker door de opname van 89-zirconium gelabeld cetuximab te beoordelen middels PET-scaMetastatic colorecal adenocarcinoma, K-RAS and N-RAS wild type.
NL-OMON26385VU University Medical Center (central site)UMC GroningenRadboud UMC85
Terminated
Phase 1
Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal CancerMetastatic Colorectal Cancer
NCT02117466Amsterdam UMC, location VUmc85
Completed
Not Applicable
Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PETmetastazised colorectal canceradvanced intestinal cancer10017991
NL-OMON36409Vrije Universiteit Medisch Centrum38
Active, not recruiting
Phase 1
Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PET - COLO CETUXadvanced colorectal cancerMedDRA version: 12.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancer
EUCTR2010-021943-41-NLVU Medical Center38